Oppenheimer Rates Definium Therapeutics (DFTX) buy
Oppenheimer has reiterated its buy rating for Definium Therapeutics with a $60 price target, a 42.42% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Oppenheimer rated Definium Therapeutics, Inc. ($DFTX) "buy" with a $60 price target on June 22, 2026.
Since the rating, $DFTX is up 26.9% after 1 week, up 19.1% after 1 month and down 12.5% to date (from the $36.67 close on Jun 22, 2026).
DFTX
Definium Therapeutics, Inc.
Key Points
- Oppenheimer reiterated its buy rating on Definium Therapeutics, Inc. (DFTX), setting a price target of $60 on June 22, 2026.
- The stock is currently trading at $42.13, which is well below the target price, indicating potential upside.
- Definium Therapeutics has a market cap of about $5.28 billion and is focused on developing treatments for brain health disorders.
Get $DFTX trade alerts by text
We text you when insiders, Congress or big funds trade $DFTX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Definium Therapeutics, Inc. alert may contain errors. Disclosures
Oppenheimer's Latest Rating on Definium
On June 22, 2026, Oppenheimer reiterated its buy rating on Definium Therapeutics, Inc. (DFTX) with a price target of $60. The stock's current price is $42.13, suggesting it has room for growth towards the target.
Oppenheimer vs. the S&P 500
Hypothetical returns from Oppenheimer's disclosed trades, not real profit or advice. How we model this.
Comparing Ratings Across Wall Street
Oppenheimer's rating is part of a broader positive sentiment on Wall Street. Canaccord Genuity recently maintained a buy rating on Definium with a target of $58, while other firms like JP Morgan, Baird, and Needham have also issued favorable ratings with targets ranging from $66 to $84. This shows a consensus among several analysts that the stock has significant upside potential.
Stock Performance Context
Currently, Definium's stock trades at $42.13, which is notably above its 52-week low of $9.35 but below its high of $49.70. The stock's price is close to its 50-day moving average of $42.28. This positioning may indicate that the stock is consolidating after previous gains, as analysts remain optimistic about its future.
$DFTX price target
Definium Therapeutics, Inc. daily closes and this analyst's $60 target. Not advice.
Insider Buying and Selling at Definium Therapeutics, Inc.
Several insiders at Definium Therapeutics have recently sold shares. Chief Financial Officer Brandi Roberts sold 3,013 shares on June 25, 2026, at an average price of $45.03, totaling about $135,675. Chief Commercial Officer Matthew Wiley sold 2,867 shares for approximately $129,101, while Chief Legal Officer Mark Sullivan sold 13,008 shares valued at around $585,750. Chief Medical Officer Daniel Karlin also sold 10,035 shares for about $451,876. These transactions were planned and do not necessarily indicate negative sentiment.
Upcoming Earnings
Definium Therapeutics is set to report its next earnings on November 5, 2026. Investors will be watching closely to see how the company’s performance aligns with analyst expectations and market sentiment.
About Definium Therapeutics
Definium Therapeutics, Inc., based in New York, develops innovative treatments for brain health disorders. Its lead products are in advanced clinical trials, including DT120 for anxiety and depression and DT402 for autism spectrum disorder. This focus on mental health aligns with current healthcare trends and investor interest.
What's Ahead for Definium Therapeutics, Inc.
As Definium prepares for its upcoming earnings report, analysts will be focused on how the company’s clinical trials progress and the impact on its stock price. With Oppenheimer's buy rating and a $60 target, investors will be keen to see if the stock can reach this level in the coming months.
Related Filing Alerts
Source: Oppenheimer's rating change on $DFTX (Jun 22, 2026). Written by software, not financial advice. How we make alerts